Extract
In 2013, the European Respiratory Society (ERS) established the Clinical Research Collaborations (CRC) programme [1] with the aim to support research in different areas of respiratory medicine through European-wide multicentre networks of researchers, from both within and outside of the Society. CRCs are built on multidisciplinary pan-European networks of researchers in specific disease areas, with the aim of building research infrastructures (cohorts, databases,etc.), identifying outstanding research questions, developing innovative research protocols, conducting large-scale clinical studies and facilitating the search for external funding. The CRC programme [2] is overseen by the CRC Director who, supported by the CRC working group, regularly reports to the ERS Science Council.
Abstract
This editorial describes the ERS CRC programme, which addresses research areas across all major respiratory disease domains. It explains how the ERS Research Agency supports the CRCs to obtain external funding and ensures links with other ERS activities.https://bit.ly/2WHIQPa
Footnotes
Conflict of interest: M. van den Berge declares research grants (paid to institution) from GlaxoSmithKline, Roche, Genentech, Sanofi, AstraZeneca and Novartis, in the 36 months prior to manuscript submission.
Conflict of interest: C. Genton is an employee of the European Respiratory Society.
Conflict of interest: E. Heuvelin is an employee of the European Respiratory Society.
Conflict of interest: A.K. Simonds has nothing to disclose.
Conflict of interest: M. Humbert has nothing to disclose.
Conflict of interest: A. Nyberg has nothing to disclose.
利益冲突:r . Gosens声明research grants (paid to institution) from Aquilo, Sanofi-Genzyme and Boehringer Ingelheim, in the 36 months prior to manuscript submission.
Conflict of interest: L. Donnelly has nothing to disclose.
Conflict of interest: O. Fulton has nothing to disclose.
Conflict of interest: M. Wilkens has nothing to disclose.
Conflict of interest: N. Roche declares research grants (paid to institution) from GlaxoSmithKline, Boehringer Ingelheim, Pfizer and Novartis; consulting fees from Boehringer Ingelheim, Novartis, Pfizer, Teva, GlaxoSmithKline, AstraZeneca, Chiesi, Sanofi and Zambon; and honoraria for speaking or writing from Boehringer Ingelheim, Novartis, Pfizer, Teva, GlaxoSmithKline, AstraZeneca, Chiesi, Sanofi and Zambon, all in the 30 months prior to manuscript submission.
Conflict of interest: C. Brightling has nothing to disclose.
- ReceivedSeptember 20, 2021.
- AcceptedSeptember 22, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contactpermissions{at}ersnet.org